AA
VRDN icon

AlphaCentric Advisors’s Viridian Therapeutics VRDN Stock Holding History

AlphaCentric Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-15,000
Closed -$341K – 285
2024
Q3 		$341K Buy
15,000
+2,500
+20% +$40.9K 0.25% 102
2024
Q2 		$163K Buy
12,500
+6,500
+108% +$90K 0.12% 137
2024
Q1 		$105K Buy
+6,000
New +$116K 0.06% 186
2023
Q4 		– Sell
-80,000
Closed -$1.23M – 286
2023
Q3 		$1.23M Buy
80,000
+44,500
+125% +$849K 0.7% 47
2023
Q2 		$845K Hold
35,500
– – 0.47% 75
2023
Q1 		$903K Hold
35,500
– – 0.62% 58
2022
Q4 		$1.04M Hold
35,500
– – 1.02% 34
2022
Q3 		$728K Buy
+35,500
New +$638K 0.75% 45

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

AlphaCentric Advisors's VRDN Position: Q4 2024 in Review

AlphaCentric Advisors sold out of Viridian Therapeutics (VRDN) in Q4 2024, closing a stake of 15,000 shares — an estimated $341K sold.

AlphaCentric Advisors first reported a position in VRDN in Q3 2022 and held it in 8 quarters. The position peaked at $1.23M in Q3 2023. 178 funds tracked by Wall St. Rank hold VRDN as of Q4 2024.

  • AlphaCentric Advisors reported no remaining Viridian Therapeutics position as of Q4 2024 after selling out during the quarter.
  • AlphaCentric Advisors sold 15,000 Viridian Therapeutics shares in Q4 2024, an estimated $341K.
  • AlphaCentric Advisors first reported a position in Viridian Therapeutics in Q3 2022 and held it in 8 quarters.
  • AlphaCentric Advisors's Viridian Therapeutics position peaked at $1.23M in Q3 2023.
  • 178 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q4 2024.

Based on AlphaCentric Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.